Methods and compositions for cell-proliferation-related disorders
AssigneeAgios Pharmaceuticals, Inc.
InventorsLenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
Life of this patent
Estimating the term…
Abstract
Methods of treating and evaluating subjects having neoactive mutants are described herein.
Claims12
A method of treating a subject having acute myelogenous leukemia (AML) characterized by the presence of a mutant isocitrate dehydrogenase 1 enzyme (IDH1) or a mutant isocitrate dehydrogenase 2 enzyme (IDH2), wherein the mutant IDH1 or mutant IDH2 has the ability to convert alpha-ketoglutarate to 2-hydroxyglutarate (2HG), the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of said mutant IDH1 or mutant IDH2.
Dependencies are inferred from the claim text.